Publications by authors named "Jaesh Naik"

Claim this Profile
C
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.
Philipp Ivanyi, Ash Bullement, Andrea Botticelli, Francesco Perri, Giorgio L Colombo, Jaesh Naik

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.
María Presa, David Vicente, Antonio Calles, Laura Salinas-Ortega, Jaesh Naik

Clinicoecon Outcomes Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Jaesh Naik, Norma Beavers, Fredrik O L Nilsson, Laura Iadeluca, Chrissy Lowry

Appl Health Econ Health Policy· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia.
Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang

J Comp Eff Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms.
Joe Yang, Jaesh Naik, Matthew Massello, Lewis Ralph, Ryan James Dillon

Infect Dis Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms.
Joe Yang, Jaesh Naik, Matthew Massello, Lewis Ralph, Ryan James Dillon

Infect Dis Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Jaesh Naik, Laura Puzniak, Simone Critchlow, David Elsea, Ryan James Dillon

Infect Dis Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis